Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
acapatamab
- Development stage
- Discontinued
- Lead developer
- Amgen
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Acapatamab is a half-life extended bispecific T cell engager (BiTE) antibody targeting both prostate-specific membrane antigen (PSMA) and CD3. Upon administration, it binds to CD3 on cytotoxic T lymphocytes and PSMA on tumor cells, activating and redirecting T cells to kill PSMA-expressing tumor cells through cytotoxic mechanisms. Acapatamab was developed primarily for the treatment of metastatic castration-resistant prostate cancer (mCRPC), particularly in patients refractory to androgen receptor pathway inhibitors and taxane-based chemotherapy. The drug demonstrated pharmacodynamic activity by inducing rapid T-cell activation and cytokine production, with a manageable safety profile but limited durable antitumor efficacy in clinical trials[1][4][6].
- Other names
- AMG 160AMG160AMG-160
02
Targets
CD3 (T-cell surface glycoprotein CD3)
Beyond the preview
Go deeper on acapatamab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on acapatamab.